Mandal AK , Mercado A , Foster A , Zandi-Nejad K , Mount DB .

MC_U137961142 Medical Research Council , MC_UU_12009/8 Medical Research Council , Medical Research Council , MC_U137981013 Medical Research Council , MC_U137961146 Medical Research Council , PG/09/082/28020 British Heart Foundation , G1000729 Medical Research Council , P01 DK070756 NIDDK NIH HHS , R01 DK057708 NIDDK NIH HHS , R21 AR065968 NIAMS NIH HHS

	Figure 1. Tranilast inhibits urate transport mediated by the human urate transporter URAT1 expressed in Xenopus laevis oocytes. (A) Time course of [14C]‐urate uptake by control and URAT1‐expressing oocytes. [14C]‐urate uptake by URAT1‐expressing oocytes was trans‐stimulated by preinjecting with 50 nL of 100 mmol/L PZA or nicotinate (Nico) 2 h before [14C]‐urate uptake experiment. Urate uptakes in the control oocytes were identical, resulting in superimposed data. Inset, western blot analysis of URAT1 protein expressed in oocytes. (B) [14C]‐urate transport properties of URAT1: voltage sensitivity and Na+‐dependence was examined by replacing extracellular NaCl by KCl or LiCl. Chloride effects were also examined; for the 0 Cl− bath, NaCl was replaced by Na‐gluconate (Na‐Gluc), KCl by K‐gluconate (K‐Gluc), MgCl2 by Mg‐gluconate, and CaCl2 by Ca‐gluconate. *P < 0.001 compared with NaCl (ND96). (C) Trans‐stimulatory effects of preloaded organic anions on [14C]‐urate uptake by URAT1‐expressing oocytes: [14C]‐urate uptake rate via URAT1 was measured in URAT1‐expressing oocytes preloaded with 50 nL of 100 mmol/L Lac, Nico, PZA, PAH, BHB or salicylate (Sal). *P < 0.001 compared with water‐injected control; NS, not significant. (D). Inhibition of [14C]urate by URAT1 in the presence of extracellular organic anions or uricosuric drugs, including tranilast: the uptake of [14C]‐urate (40 μmol/L) by URAT1‐expressing oocytes in exchange of preloaded intracellular nicotinate was determined after 1 h in the absence or presence of inhibitors (uricosuric drugs or organic anions) that were added to the extracellular medium (pH 7.4) at the indicated concentrations. *P < 0.001 compared with DMSO. Tran, Benz, Prob, DMSO. Data are mean ± S.E. with n = 12–15. (E) The 50% inhibitory concentration (IC 50) curve of tranilast for [14C]‐urate uptake‐mediated by URAT1 in oocytes preloaded with nicotinate. PZA, pyrazine carboxylate; PAH, para‐aminohippurate; Tran, tranilast; Benz, benzbromarone; Prob, probenecid; DMSO, dimethylsulfoxide.
	Figure 2. Tranilast inhibits urate transport mediated by the human urate transporter GLUT9a. (A) Time course of [14C]‐urate uptake by control and GLUT9a‐expressing oocytes. Inset, western blot analysis of GLUT9a protein expressed in oocytes. (B) [14C]urate transport properties of GLUT9a: voltage sensitivity and Na+‐dependence was examined by replacing extracellular NaCl by KCl or LiCl. We also assessed [14C]‐urate uptake by GLUT9a in the absence of extracellular Cl− ion (0 Cl−); in 0 Cl− bath, NaCl was replaced by Na‐gluconate (Na‐Gluc), KCl by k‐gluconate (K‐Gluc), MgCl2 by Mg‐gluconate, and CaCl2 by Ca‐gluconate. Asterisk, P < 0.001 compared with NaCl (ND96); NS, not significant. (C) Inhibition of [14C]‐urate uptake by GLUT9a in the presence of antiuricosuric or uricosuric drugs: The uptake of [14C]‐urate (40 μmol/L) by GLUT9a‐expressing oocytes was determined in complete absence of Na+ (NaCl of ND96 medium was replaced by KCl) after 1 h in the absence or presence of inhibitors (uricosuric drugs) which were added to the extracellular medium (pH 7.4) at the indicated concentrations. *P < 0.001 compared with DMSO. (D) Inhibition of [14C]‐urate uptake by GLUT9a in depolarized cells. The uptake of [14C]‐urate (40 μmol/L) by GLUT9a‐expressing oocytes was determined in the complete absence of Na+ (NaCl of ND96 medium was replaced by KCl) after 1 h in the absence or presence of inhibitors (uricosuric drugs) at the indicated concentrations. *P < 0.001 compared with DMSO. Tran, Benz Prob, Sal, DMSO. Data are mean ± S.E. with n = 12–15. Data are mean ± S.E. with n = 12–15. (D) The 50% inhibitory concentration (IC 50) curve of tranilast for [14C]‐urate uptake via GLUT9a. Tran, tranilast; Benz, benzbromarone; Prob, probenecid; Sal, salicylate; DMSO, dimethylsulfoxide.
	Figure 3. Tranilast inhibits urate transport mediated by the human urate/dicarboxylate exchanger OAT4. (A) The uptake of [14C]‐urate by OAT4‐expressing oocytes was performed in ND96 medium (pH 7.4) at ~25°C for 1 h. Na+‐dependence was examined by replacing extracellular NaCl by KCl. The [14C]‐urate uptake by OAT4‐expressing oocytes was found to be significantly trans‐stimulated when OAT4‐expressing oocytes were preinjected with 50 nL of 100 mmol/L maleate (Mal); preinjection with 50 nL of 100 mmol/L succinate (Succi), α‐ketogluterate (α‐KG), nicotinate (Nico), or PZA had no significant effects. Asterisk, P < 0.001 compared with water‐injected control. (B) The inhibition of [14C]‐urate uptake by OAT4 was examined in the presence of extracellular organic anions (for cis‐inhibition) or uricosuric drugs at the indicated concentrations. Asterisk, P < 0.001 compared with DMSO/NaCl(ND96). Tran, Benz, Prob, DMSO. Data are mean ± S.E. with n = 12–15. PZA, pyrazine carboxylate; Tran, Tranilast; Benz, Benzbromarone; Prob, probenecid; DMSO, dimethylsulfoxide; Lac, lactate; Nico, nicotinate.
	Figure 4. Tranilast inhibits urate transport mediated by the human urate transporter OAT10. (A) Time course of [14C]‐urate uptake by control and URAT1‐expressing oocytes. [14C]‐urate uptake by OAT10‐expressing oocytes was trans‐stimulated by preinjecting with 50 nL of 100 mmol/L PZA 2 h. Inset, western blot analysis of OAT10 protein expressed in oocytes. (B) Trans‐stimulatory effects of preloaded organic anions on [14C]‐urate uptake by OAT10‐expressing oocytes: [14C]‐urate uptake rate mediated by OAT10 was measured in OAT10‐expressing oocytes preloaded with 50 nL of 100 mmol/L Lac, Nico, PZA, PAH, BHB, α‐ketoglutarate (α‐KG) or succinate (Succi). *P < 0.001 compared with water‐injected control. (C) [14C]‐urate transport properties of OAT10: voltage sensitivity and Na+‐dependence was examined by replacing extracellular NaCl by KCl or LiCl. Existence of urate/Cl− exchange mechanism or Cl− dependence or cis‐inhibitory effects of extracellular Cl− on was verified by [14C]‐urate uptake via OAT10 in the absence of extracellular Cl− ion (0 Cl−). In 0 Cl− bath, NaCl was replaced by Na‐gluconate (Na‐Gluc), KCl by k‐gluconate (K‐Gluc), MgCl2 by Mg‐gluconate, and CaCl2 by Ca‐gluconate. Asterisk, P < 0.001 compared with NaCl (ND96); NS, not significant. (D) Inhibition of [14C]‐urate by OAT10 in the presence of extracellular organic anions or uricosuric drugs: The uptake of [14C]‐urate (40 μmol/L) by OAT10‐expressing oocytes in exchange of preloaded intracellular PZA was determined after 1 h in the absence or presence of inhibitors (uricosuric drugs) that were added to the extracellular medium at the indicated concentrations. *P < 0.001 compared with NaCl (ND96). Tran, Benz, Prob, DMSO. Data are mean ± S.E. with n = 12–15. (E) The 50% inhibitory concentration (IC 50) curve of tranilast for [14C]‐urate uptake via OAT10 in oocytes preloaded with PZA. PZA, pyrazine carboxylate; PAH, para‐aminohippurate; Lac, lactate; Nico, nicotinate; PZA, pyrazine carboxylate; Tran, tranilast; Benz, benzbromarone; Prob, probenecid; DMSO, dimethylsulfoxide.
	Figure 5. Tranilast inhibits urate transport activity of URAT1 and GLUT9a in a noncompetitive (mixed) manner. (A) The kinetic curve of URAT1‐mediated [14C]‐urate uptake in the absence or presence of inhibitor (cold urate or tranilast). (B) The kinetic curve of GLUT9a‐mediated [14C]‐urate uptake in the absence or presence of inhibitor (cold urate or tranilast). (C) Eadie–Hofstee plot of URAT1‐mediated [14C]‐urate uptake in the absence or presence of inhibitor. (D) Eadie–Hofstee plot of GLUT9a‐mediated [14C]‐urate uptake in the absence or presence of inhibitor. V, the [14C]‐urate uptake rate in pmol/oocyte/h; V/S, [14C]‐urate uptake rate per concentration (μmol/L) of [14C]‐urate; open circle, in the absence of inhibitor; open circle, in the absence of inhibitor; open triangle, in the presence 50 μmol/L cold urate; closed circle 15 or 20 μmol/L tranilast; closed triangle 30 or 40 μmol/L tranilast. Tran, Benz, Prob, SalDMSO, W, oocytes were washed out of drugs with uptake medium. Data are mean ± S.E. with n = 12–15. Tran, Tranilast; Benz, Benzbromarone; Prob, probenecid; Sal, salicylate; DMSO, dimethylsulfoxide; W, oocytes were washed out of drugs with uptake medium.
	Figure 6. Functional characterization of human URAT1 as a nicotinate transporter; effects of uricosuric drugs. (A) Trans‐stimulatory effects of preloaded organic anions on [14C]‐nicotinate uptake by URAT1‐expressing oocytes: [14C]‐nicotinate transport rate via URAT1 was measured in URAT1‐expressing oocytes preloaded with 50 nL of 100 mmol/L Lac, PZA, PAH, BHB, or urate. *P < 0.001 compared with water‐injected control; NS, not significant. (B) Inhibition of [14C]‐nicotinate by URAT1 in the presence of extracellular urate or uricosuric drugs: The uptake of [14C]‐nicotinate (40 μmol/L) by URAT1‐expressing oocytes in exchange of preloaded intracellular PZA was determined after 1 h in the absence or presence of inhibitors (uricosuric drugs) that were added to the extracellular medium (pH 7.4) at the indicated concentrations. *P < 0.001 compared with DMSO/NaCl(ND96). Tran, Benz, Prob, DMSO. (C) The 50% inhibitory concentration (IC 50) curve of tranilast for [14C]‐nicotinate uptake by URAT1‐expressing oocytes preinjected with 50 nL of 100 mmol/L PZA 2 h before [14C]‐nicotinate uptake experiment. Data are mean ± S.E. with n = 12–15. BHB, β‐hydroxy butyrate; PAH, para‐aminohippurate; Lac, lactate, PZA, pyrazine carboxylate; PAHe , para‐aminohippurate; Tran, Tranilast; Benz, Benzbromarone.
	Figure 7. Functional and pharmacological characterization of human nicotinate transporters, hSMCT1, SMCT2, and OAT10. The uptake of [14C]‐nicotinate (40 μmol/L) by SMCT1‐, SMCT2‐ or OAT10‐expressing oocytes was performed in ND96 medium (pH 7.4) at ~25°C. [14C]‐nicotinate transport properties of nicotinate transporters: voltage sensitivity and Na+‐dependence was examined by replacing extracellular NaCl by KCl or LiCl. Chloride ion‐dependence was also assessed; in 0 Cl− bath, NaCl was replaced by Na‐gluconate (Na‐Gluc), KCl by K‐gluconate (K‐Gluc), MgCl2 by Mg‐gluconate, and CaCl2 by Ca‐gluconate. (A) [14C]‐nicotinate transport properties of human SMCT1 (B) [14C]nicotinate transport properties of human SMCT2. *P < 0.001 compared with NaCl (ND96). (C) Inhibition of [14C]‐nicotinate uptake via SMCT1, and SMCT2 in the presence of uricosuric drugs added into the extracellular medium (pH 7.4) at the indicated concentrations. P < 0.01 compared with NaCl (ND96); NS, not significant. (D) [14C]‐nicotinate transport properties of human OAT10 in oocytes preloaded with PZA. *P < 0.001 compared with uptake in the absence of inhibitor; NS, not significant. (E) Inhibition of [14C]‐nicotinate uptake via OAT10 (preloaded with PZA) in the presence of uricosuric drugs added into the extracellular medium (pH 7.4) at the indicated concentrations. P < 0.01 compared with NaCl (ND96); NS, not significant. Tran, Benz, Prob, DMSO. Data are mean ± S.E. with n = 12–15. PZA, pyrazine carboxylate; Tran, Tranilast; Benz, Benzbromarone; Prob, probenecid; DMSO, dimethylsulfoxide.
	Figure 8. Tranilast inhibits urate transport mediated by the human urate transporter NPT1. The uptake of [14C]‐urate by NPT1‐expressing oocytes was performed in ND96 medium (pH 7.4) at ~25°C for 1 h. The [14C]‐urate uptake by NPT1‐expressing oocytes was found little trans‐stimulated when NPT1‐expressing oocytes were preinjected with 50 nL of 100 mmol/L nicotinate (Nico) 2 h before [14C]‐urate uptake experiment. The [14C]‐urate uptake by NPT1 was found substantially inhibited in the presence of extracellular organic anions or uricosuric drugs. Organic anions or uricosuric drugs were added to the extracellular medium (pH 7.4) at the indicated concentrations. *P < 0.001 compared with uptake in the presence of DMSO or in the absence of inhibitor. Tran, Benz, Prob, DMSO, PZA, Sal. Data are mean ± S.E. with n = 12–15. PZA, pyrazine carboxylate; Tran, Tranilast; Benz, Benzbromarone; Prob, probenecid; DMSO, dimethylsulfoxide.
	Figure 9. Urate efflux mediated by the human urate transporter ABCG2 is unaffected by tranilast. Control or ABCG2‐expressing oocytes were preinjected with 50 nL of 500 μmol/L 14C]‐urate [dissolved in efflux medium (ND96, pH 7.4)], incubated in ND96 medium for 1 h at 16°C for recovery. Oocytes were washed in cold efflux medium four times and then subjected to efflux for 1 h at room temperature (~25°C) in ND96 medium (pH 7.4) in the absence or presence of drug. The amount of [14C]‐urate retained in each oocyte after 60 min of efflux is shown here. *P < 0.001 compared with urate efflux in the absence of any inhibitor. Tran, Benz, Prob, DMSO. All data are mean ± S.E.M. with n = 12–15. PZA, pyrazine carboxylate; Tran, Tranilast; Benz, Benzbromarone; Prob, probenecid; DMSO, dimethylsulfoxide. Prob, probenecid; DMSO, dimethylsulfoxide.
	Figure 10. Tranilast inhibits urate transport mediated by urate transporter OAT3 and OAT1. The uptake of [14C]‐urate (40 μmol/L) was performed in ND96 medium (pH 7.4) at ~25°C for 1 h. (A) The [14C]‐urate uptake by mouse OAT3 in oocytes remained unaffected if oocytes were preinjected with 50 nL of 100 mmol/L PZA but cis‐inhibited by 10 mmol/L PZA, nicotinate (Nico), or salicylate (Sal). The [14C]‐urate uptake by OAT3‐expressing oocytes was effectively inhibited by 50 μmol/L tranilast (Tran), 100 μmol/L benzbromarone (Benz) or 1.0 mmol/L probenecid (Prob). (B) The [14C]‐urate uptake by human OAT1 in oocytes was effectively inhibited by 100 μmol/L tranilast (Tran), 100 μmol/L benzbromarone (Benz) or 1.0 mmol/L probenecid (Prob). Data are mean ± S.E. with n = 12–15. *P < 0.001 compared with uptake in the presence of DMSO or in the absence of inhibitor. PZA, pyrazine carboxylate; Tran, Tranilast; Benz, Benzbromarone; Prob, probenecid; DMSO, dimethylsulfoxide.

Anzai, Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. 2008, Pubmed, Xenbase

Anzai, Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. 2008, Pubmed , Xenbase
Ascherio, Urate as a predictor of the rate of clinical decline in Parkinson disease. 2009, Pubmed
Bahn, Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13). 2008, Pubmed , Xenbase
Bibert, Mouse GLUT9: evidences for a urate uniporter. 2009, Pubmed , Xenbase
Borstad, Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. 2004, Pubmed
Cheng, Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. 1973, Pubmed
Choi, Pathogenesis of gout. 2005, Pubmed
Coady, The human tumour suppressor gene SLC5A8 expresses a Na+-monocarboxylate cotransporter. 2004, Pubmed , Xenbase
Dinour, Homozygous SLC2A9 mutations cause severe renal hypouricemia. 2010, Pubmed , Xenbase
Doria, Diabetes: Lowering serum uric acid levels to prevent kidney failure. 2011, Pubmed
Döring, SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. 2008, Pubmed
Enomoto, Molecular identification of a renal urate anion exchanger that regulates blood urate levels. 2002, Pubmed , Xenbase
Eraly, Multiple organic anion transporters contribute to net renal excretion of uric acid. 2008, Pubmed
Feig, Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. 2008, Pubmed
Ficociello, High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. 2010, Pubmed
Fleischmann, Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. 2014, Pubmed
Forman, Uric acid and insulin sensitivity and risk of incident hypertension. 2009, Pubmed
Gershon, Pharmacologic effects of nicotinic acid on human purine metabolism. 1974, Pubmed
GOLDFINGER, RENAL RETENTION OF URIC ACID INDUCED BY INFUSION OF BETA-HYDROXYBUTYRATE AND ACETOACETATE. 1965, Pubmed
Guggino, Paradoxical effects of pyrazinoate and nicotinate on urate transport in dog renal microvillus membranes. 1985, Pubmed
Hagos, Human renal organic anion transporter 4 operates as an asymmetric urate transporter. 2007, Pubmed , Xenbase
Hooper, Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. 1998, Pubmed
Hu, Activation of aryl hydrocarbon receptor (ahr) by tranilast, an anti-allergy drug, promotes miR-302 expression and cell reprogramming. 2013, Pubmed
Huls, The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. 2008, Pubmed
Iharada, Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter. 2010, Pubmed
Iwanaga, Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. 2007, Pubmed , Xenbase
Iwanaga, Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. 2005, Pubmed , Xenbase
Jutabha, Identification of a novel voltage-driven organic anion transporter present at apical membrane of renal proximal tubule. 2003, Pubmed , Xenbase
Jutabha, Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. 2010, Pubmed , Xenbase
Liu, A metabolic profiling analysis of symptomatic gout in human serum and urine using high performance liquid chromatography-diode array detector technique. 2011, Pubmed
Mandal, Uricosuric targets of tranilast. 2021, Pubmed , Xenbase
Mandal, The molecular physiology of uric acid homeostasis. 2015, Pubmed
Manganel, Sodium-pyrazinoate cotransport in rabbit renal brush border membrane vesicles. 1985, Pubmed
Matsuo, Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. 2009, Pubmed
Matsuo, Identification of ABCG2 dysfunction as a major factor contributing to gout. 2011, Pubmed
Mifsud, Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy. 2003, Pubmed
Mihara, TRPV2 ion channels expressed in inhibitory motor neurons of gastric myenteric plexus contribute to gastric adaptive relaxation and gastric emptying in mice. 2013, Pubmed
Miyachi, The effect of tranilast of the generation of reactive oxygen species. 1987, Pubmed
Miyauchi, Functional identification of SLC5A8, a tumor suppressor down-regulated in colon cancer, as a Na(+)-coupled transporter for short-chain fatty acids. 2004, Pubmed , Xenbase
Mount, Cloning and characterization of KCC3 and KCC4, new members of the cation-chloride cotransporter gene family. 1999, Pubmed , Xenbase
Munn, Prevention of allogeneic fetal rejection by tryptophan catabolism. 1998, Pubmed
Perlstein, Uric acid and the development of hypertension: the normative aging study. 2006, Pubmed
Rizwan, The chloride dependence of the human organic anion transporter 1 (hOAT1) is blunted by mutation of a single amino acid. 2007, Pubmed , Xenbase
Roch-Ramel, Renal Transport of Urate in Humans. 1999, Pubmed
Rogosnitzky, Therapeutic potential of tranilast, an anti-allergy drug, in proliferative disorders. 2012, Pubmed
Rosolowsky, High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. 2008, Pubmed
Sastre, Opposite effect of mast cell stabilizers ketotifen and tranilast on the vasoconstrictor response to electrical field stimulation in rat mesenteric artery. 2013, Pubmed
SHAPIRO, Hyperuricemia due to pyrazinamide. 1957, Pubmed
Spitsin, Role of uric acid in Alzheimer's disease. 2010, Pubmed
Srinivas, Cloning and functional identification of slc5a12 as a sodium-coupled low-affinity transporter for monocarboxylates (SMCT2). 2005, Pubmed , Xenbase
Tao, Tranilast prevents the progression of chronic cyclosporine nephrotoxicity through regulation of transforming growth factor β/Smad pathways. 2011, Pubmed
Uetake, Effect of fenofibrate on uric acid metabolism and urate transporter 1. 2010, Pubmed
Van Aubel, Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. 2005, Pubmed
Vitart, SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. 2008, Pubmed , Xenbase
Wallace, Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. 2008, Pubmed
Weisskopf, Plasma urate and risk of Parkinson's disease. 2007, Pubmed
Witkowska, Human SLC2A9a and SLC2A9b isoforms mediate electrogenic transport of urate with different characteristics in the presence of hexoses. 2012, Pubmed , Xenbase
Woodward, Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. 2009, Pubmed , Xenbase